Development and evaluation of a novel RT-qPCR assay for detection of Crimean Congo haemorrhagic fever virus using the Genedrive® point-of-care platform

ElsevierVolume 182, February 2026, 105889Journal of Clinical VirologyAuthor links open overlay panel, , , , , , , , , , , , , , , , , Highlights•

Design and evaluation of a RT-qPCR for CCHF.

Sample lysis and RT-qPCR in the same cartridge.

Sensitive and specific detection of CCHFV from serum.

AbstractIntroduction

Crimean-Congo haemorrhagic fever (CCHF) is a viral haemorrhagic fever classed by the World Health Organization as a priority disease due to the lack of countermeasures. A point-of-care (POC) diagnostic test for rapid detection of positive cases to expedite patient management is not currently available but urgently needed.

Methods

We have developed an RT-qPCR assay to be used with the commercially available POC Genedrive® PCR platform enabling viral detection in serum with minimal sample preparation. The sensitivity and specificity of the novel assay in the Genedrive® was evaluated against the RealStar® CCHFV RT-qPCR Kit (Altona Diagnostics, Germany).

Results

The sensitivity and specificity in assay V1 (sample n = 150) were 94.4 % (95 % CI, 88.2–97.9) and 97.6 % (95 % CI, 87.1–99.9). For assay (n = 55) V2 sensitivity was 92.3 % (95 % CI, 74.9–99.5) and specificity was 100 % (95 % CI, 87.7–100).

Conclusions

This study supports the feasibility of diagnosing CCHF using POC RT-qPCR platforms, having the potential to reduce turnaround times, leading to improved clinical management.

Keywords

CCHF

QPCR

Molecular diagnostics

Assay design

Assay evaluation

© 2025 The Authors. Published by Elsevier B.V.

Comments (0)

No login
gif